Sana Biotechnology, Inc.

NASDAQ: SANA · Healthcare · Biotechnology

PublicHQ Seattle, WA · KingCIK 0001770121Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 33DQ —GM —SS 57

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$244.2M

Employees

142

as of 2026-09-10

Market cap

$882.2M

as of 2026-09-10

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$244.2M-$244.2M2025

Operating income-$250.3M-$250.3M2025

Total assets$416.9M$416.9M2025

Liabilities$256.0M$256.0M2025

Equity$160.9M$160.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Sana Biotechnology, Inc.’s financial profile?

Sana Biotechnology, Inc. earned -$244.2M in FY2025 net income.

Peers · Healthcare

Attovia Therapeutics, Inc.——Faeth Therapeutics, Inc.——Olema Pharmaceuticals, Inc.——SpyGlass Pharma, Inc. Common Stock——Climb Bio, Inc.——Cybin Inc. Common Stock——

Neighbors

King →

Microsoft Corporation$281.7B——Amazon.com, Inc.$716.9B87A Costco Wholesale Corporation$275.2B84B+T-Mobile US, Inc.$88.3B84B+Starbucks Corporation$37.2B74B PACCAR Inc$28.4B74B

Key facts

CEOSteven D. Harr

SectorHealthcare

IndustryBiotechnology

HeadquartersSeattle, WA

ExchangeNASDAQ: SANA

Employees142

IPO date2021-02-04

Latest filings

8-K2026-09-08 10-Q2026-08-10 8-K2026-08-10 8-K2026-06-05 8-K2026-05-15 8-K2026-05-11 10-Q2026-05-11 8-K2026-04-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.